Impedimed Limited (AU:IPD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ImpediMed Limited has announced that two more payors, Emblem Health and Presbyterian Health, have endorsed their Bioimpedance Spectroscopy (BIS) technology for lymphedema assessment, expanding coverage to 144 million lives across 16 states. With this inclusion, 18 private payors now provide positive coverage, reflecting significant commercial progress and enhanced patient access to early lymphedema screening in the U.S. The company’s growth is anchored by its SOZO Digital Health Platform, which remains the only FDA-cleared BIS technology for lymphedema assessment.
For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.
